Yahoo Finance

• Revenue: DKK8 million for Q1 2025, primarily from the license and development agreement for Zegalogue with Novo Nordisk.

• Research and Development Expenses: DKK290 million, driven by the development of petrelintide and related trials.

• Sales and Marketing Expenses: DKK37 million, mainly for pre-commercial activities related to rare disease assets.

• General and Administrative Expenses: DKK65 million, reflecting organizational strengthening and investments in IT and patents.

• Net Financial Items: DKK70 million, primarily from interest income on market securities.

• Cash Position: DKK8.5 billion as of March 31, 2025, expected to increase to approximately DKK18 billion after receiving the USD1.4 billion up-front payment from Roche.

• Financial Guidance: Net operating expenses projected between DKK2 billion and DKK2.5 billion for 2025, excluding Roche transaction costs.

• Warning! GuruFocus has detected 5 Warning Signs with ZLDPF.

Release Date: May 08, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Zealand Pharma AS (ZLDPF) has entered a transformative collaboration with Roche on petrelintide, including co-development and co-commercialization rights with a 50/50 profit sharing in the US and Europe.

• The company has a strong financial position, with a cash equivalent and marketable securities totaling DKK8.5 billion as of March 31, 2025, and expects to receive a USD1.4 billion up-front payment from Roche.

• Zealand Pharma AS (ZLDPF) has a differentiated mid-to-late-stage obesity pipeline, with a focus on amylin analogs, which have shown potential for effective weight management.

• The company has strengthened its organization by hiring key personnel, including a new Chief Scientific Officer and a medical advisor in obesity, to drive its research and development efforts.

• Zealand Pharma AS (ZLDPF) is committed to advancing its rare disease programs, with clear paths forward for its late-stage programs and ongoing efforts to secure partnerships.

Negative Points

• The company faces geopolitical and market uncertainties, which could impact its operations and growth plans.

• There are challenges in ensuring patient adherence to weight management therapies, as many patients struggle to stay on current treatments due to side effects.

• Zealand Pharma AS (ZLDPF) is still in the early stages of its obesity market evolution, with only about 2% of eligible patients currently on pharmacotherapy.

• The company is awaiting an inspection classification upgrade of its third-party manufacturer's facility, which affects the resubmission of its dasiglucagon application.

• There is significant competition in the amylin analog space, with other companies developing similar therapies, which could impact Zealand Pharma AS (ZLDPF)'s market position.